Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

By J. Stockman. 2010

640 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/67c5e8a23bb04f6d3b1a57c2de5f58806c0d132f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. RS Brown
2. JB Wong
3. NA Terrault
4. M. Jonas
5. B. McMahon
6. NH Bzowej
7. JP Hwang
8. A. Lok

Citations in the corpus

• Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, background): “TAF joins the list of preferred HBV therapies, along with entecavir, tenofovir disoproxil fumarate (TDF), and peginterferon (peg-IFN; Tables 1 and 2)((6-16)) (section: Updated Recommendations on the Treatment of Patients With Chronic Hepatitis B).”